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1. DISEASE CHARACTERISTICS
1.1 Name of the disease (synonyms)
Deﬁciency of GDP-Man:GlcNAc2-PP-Dol mannosyltransferase, manno-
syltransferase 1 deﬁciency, ALG1-CDG, CDG-Ik.
1.2 OMIM# of the disease
608540
1.3 Name of the analysed genes or DNA/chromosome segments:
ALG1.
1.4 OMIM# of the gene
605907.
1.5 Mutational spectrum
Thirteen variants have been reported: ten missense variants, two
splicing variants and one deletion variant. The most frequent variant
is c.773C4T (p.Ser258Leu)1–6 (www.lovd.nl/ALG1). The standard
reference sequence indicating reported variants (ENSG00000033011)
and a reference for exon numbering (ENST00000262474) can be
found at http://www.ensembl.org.
1.6 Analytical methods
Sanger sequencing of the thirteen coding exons and ﬂanking intronic
sequences of the ALG1 gene using primers designed to discriminate
between this gene and its documented pseudogenes (NCBI reference
sequence: NM_019109.4).
1.7 Analytical validation
Sanger sequencing identiﬁes the variants in 499% of patients.
Deep intronic variants, large deletions and duplications would not
be detected using this approach. Novel variants with uncertain
pathogenic nature are of course possible.
1.8 Estimated frequency of the disease
(Incidence at birth (‘birth prevalence’) or population prevalence.
If known to be variable between ethnic groups, please report):
Nineteen patients (belonging to fourteen families) have been
reported1–10 and thirteen unpublished patients (from nine families)
are known to the authors. The frequency and the prevalence of the
disease are not known.
1.9 Diagnostic setting
Yes No
A. (Differential) diagnostics ⊠
B. Predictive testing ⊠
C. Risk assessment in relatives ⊠ □
D. Prenatal ⊠ □
Comment:
ALG1-CDG belongs to the ﬁve most common N-glycosylation
disorders together with PMM2-CDG, ALG6-CDG, MPI-CDG and
SRD5A3-CDG. It is an autosomal recessive disease with a broad
clinical spectrum, and with early death at the second day of life to
survival beyond the age of 20 years.1–10 Its phenotype is characterized
by a predominant neurological involvement. Constant features are an
intellectual developmental disorder (mostly severe) and hypotonia
(sometimes only infantile). A majority of patients show dysmorphism
(facial dysmorphism, inverted nipples, fat pads, contractures, arachno-
dactyly a.o.), microcephaly (mostly neonatal), intractable seizures
(with neonatal or later onset), visual disturbances (strabismus,
nystagmus, retinopathy and/or (in some patients) severe visual loss),
tremor, ataxia, severe infections/episodes of unexplained fever and
cerebral abnormalities (cerebral infarct, general atrophy and/or
periventricular white matter abnormalities). Symptoms reported in
only one or a few patients are feeding problems, gastrointestinal
problems (diarrhoea and ascites), growth retardation, hearing loss,
areﬂexia, spastic tetraparesis, stereotypic movements, peripheral neu-
ropathy, repiratory problems (including pleural effusion), pericardial
effusion, oedema, hepatomegaly, cholestatic jaundice, portal hyperten-
sion, Budd–Chiari syndrome, nephrotic syndrome, spontaneous
haemorrhage and venous thrombosis. Biochemical abnormalities are
decreased levels of serum LDL cholesterol, blood coagulation factor XI
and anticoagulation factors antithrombin, protein C and protein S,
as well as variable hypoalbuminemia, increased serum transaminases,
decreased serum cholinesterase and immunoglobulins, and endocri-
nological abnormalities (such as decreased serum IGF1 and IGFBP3).
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Serum transferrin isoelectrofocusing, capillary zone electrophoresis or
HPLC show a type 1 pattern, and analysis of short dolichol-linked
oligosaccharides (DLO) in ﬁbroblasts shows an increase of
GlcNAc2-PP-dolichol. The diagnosis has to be conﬁrmed by mutation
analysis of ALG1. As the DLO analysis, especially of short DLO’s, is
cumbersome, produces sometimes equivocal results, and is only
available in very few centres in a research setting, an upcoming
strategy is to subject the DNA to Next-Generation Sequencing
methods such as a CDG panel of genes known to be involved in
CDG or whole-exome sequencing. The identiﬁcation of the variant
that affects function will permit heterozygote detection in the family
and prenatal diagnosis.
Since the patients with ALG1-CDG may have dysmorphic features
resembling those observed in PMM2-CDG (that is, inverted nipples,
subcutaneous fat pads), ALG1-CDG should be considered when
PMM2-CDG was searched and ruled out by PMM2 molecular
analysis.
2. TEST CHARACTERISTICS
Genotype or disease A: True positives
B: False positives
C: False negative
D: True negative
Present Absent
Test
Positive A B Sensitivity:
Speciﬁcity:
A/(A+C)
D/(D+B)
Negative C D Positive predictive value:
Negative predictive value:
A/(A+B)
D/(C+D)
2.1 Analytical sensitivity
(proportion of positive tests if the genotype is present)
Close to 100% when using the serum transferrin isoelectro-
focusing test.
2.2 Analytical speciﬁcity
(proportion of negative tests if the genotype is not present)
Close to 100% when using the serum transferrin isoelectrofocusing
test. This test can be positive in secondary glycosylation disturbances
such as galactosemia and hereditary fructose intolerance, and due to
bacterial sialidase.11–13
2.3 Clinical sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as
age or family history. In such cases a general statement should
be given, even if a quantiﬁcation can only be made case by case.
Close to 100%.
2.4 Clinical speciﬁcity
(proportion of negative tests if the disease is not present)
The clinical speciﬁcity can be dependent on variable factors such as
age or family history. In such cases a general statement should be
given, even if a quantiﬁcation can only be made case by case.
Close to 100%.
2.5 Positive clinical predictive value
(lifetime risk to develop the disease if the test is positive)
100%, based on positive serum transferrin isoelectrofocusing
screening and ALG1 mutation analysis.
2.6 Negative clinical predictive value
(probability not to develop the disease if the test is negative)
Assume an increased risk based on the family history for a
nonaffected person. Allelic and locus heterogeneity may need to be
considered.
Index case in that family had been tested:
100%
Index case in that family had not been tested:
100%
3. CLINICAL UTILITY
3.1 (Differential) diagnostics: the tested person is clinically affected
(To be answered if in 1.9 ‘A’ was marked)
3.1.1 Can a diagnosis be made other than through a genetic test?
No □ (continue with 3.1.4)
Yes ⊠
Clinically ⊠
Imaging □
Endoscopy □
Biochemistry ⊠
Electrophysiology □
Other (please describe):
3.1.2 Describe the burden of alternative diagnostic methods to the
patient
The blood sampling for the serum transferrin isoelectrofocusing
screening test and that for the mutation analysis is a minor burden
to the patient.
3.1.3 How is the cost effectiveness of alternative diagnostic methods to
be judged?
It differs among countries. In Belgium and The Netherlands the cost
of these tests is largely carried by the national assurance organism.
3.1.4 Will disease management be inﬂuenced by the result of a
genetic test?
No □
Yes ⊠
Therapy (please
describe)
Treatment of ALG1-CDG is purely symptomatic.
Prognosis (please
describe)
Molecular testing is essential for conﬁrmation of the
diagnosis and the genetic counselling of the families
concerned.
Management (please
describe)
ALG1-CDG is a multi-system disease with major neuro-
logical involvement. Follow-up by a multidisciplinary
team is important.
3.2 Predictive setting: the tested person is clinically unaffected but
carries an increased risk based on family history
(To be answered if in 1.9 ‘B’ was marked)
3.2.1 Will the result of a genetic test inﬂuence lifestyle and
prevention?
If the test result is positive (please describe):
Not applicable
If the test result is negative (please describe):
Not applicable
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3.2.2 Which options in view of lifestyle and prevention does a person
at risk have if no genetic test has been done (please describe)?
Not applicable.
3.3 Genetic risk assessment in family members of a diseased person
(To be answered if in 1.9 ‘C’ was marked)
3.3.1 Does the result of a genetic test resolve the genetic situation in
that family?
Usually yes, by testing the potential heterozygous persons (carriers) in
the family.
3.3.2 Can a genetic test in the index patient save genetic or other tests
in family members?
No.
3.3.3 Does a positive genetic test result in the index patient enable a
predictive test in a family member?
Not applicable.
3.4 Prenatal diagnosis
(To be answered if in 1.9 ‘D’ was marked)
3.4.1 Does a positive genetic test result in the index patient enable a
prenatal diagnosis?
Yes. Prenatal diagnosis should be performed by molecular analysis;
foetal transferrin isoelectrofocusing leads to false results.14
4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate
medical consequences. Is there any evidence that a genetic test is
nevertheless useful for the patient or his/her relatives? (please describe)
Knowledge of the diagnosis will stop unnecessary further investiga-
tions. It will also help the parents in the process of accepting the
disease although no curative treatment is yet available.
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